Skip to main content
. Author manuscript; available in PMC: 2024 May 25.
Published in final edited form as: J Invest Dermatol. 2023 May 19;143(11):2243–2254.e10. doi: 10.1016/j.jid.2023.04.029

Figure 6. PYC-SMAD7 promotes C/EBPβ DNA binding conferring IL22RA2 transcription expression.

Figure 6.

(a) IF visualizing IL-22RA2-expressing cells in Tat-PYC-SMAD7-treated skin. (b) IF visualizing HA-tag in PYC-SMAD7-HA transfected HaCaT cells and WT HaCaT cells. (c) Western blot using cell lysate from HaCaT and PYC-SMAD7-HA transfected HaCaT cells. (d) mRNA change by qPCR and protein expression by western blot and (e) IL-22RA2 levels by ELISA from HaCaT and PYC-SMAD7-HA transfected HaCaT cells transfected with CEBPB or Ctrl siRNA for 48 h. (f) IF showing the nucleus/cytoplasmic presences of IL-22RA2, C/EBPβ, and HA. (g) ChIP assay and (h) ChIP-qPCR for binding to ~580 base pair site of IL-22RA2 promoter. (i) IL22RA2 gene intensity of microarray data from GEO database. Data were qualified using two-tailed unpaired or paired t-test or two-way or one-way ANOVA for statistics. Data are representative of two or three independent experiments. Data represent mean ± SEM. PYC-HA-HaCaT or PYC-HaCaT: PYC-SMAD7-HA transfected HaCaT cells. ChIP, chromatin immunoprecipitation; Ctrl, control; GEO, Gene Omnibus Expression; h, hour; HA, hemagglutinin; IF, immunofluorescent; siRNA, small interfering RNA; TS, tape stripping.